What is Lytix Biopharma AS (LYTIX.OL)?

Lytix Biopharma AS (LYTIX.OL) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

Lytix Biopharma AS (LYTIX.OL)

Stock analysis · OSL · Healthcare · Biotechnology

Market Cap

N/A

PE (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

Beta

-0.53

Day Range

N/A

52-wk Range

N/A

Avg Volume

N/A

Volume

N/A

Lytix Biopharma AS (LYTIX.OL) is a publicly traded company in the Healthcare sector. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Proprietary Signals

Signal snapshot temporarily unavailable.

About Lytix Biopharma AS

Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.